Search
Efficacy of CAR-modified T cells grown with ICSR
A leukemia model in immunodeficient mice was used to determine the efficacy of CD19-specific CAR T cells grown in medium supplemented with Immune Cell Serum Replacement (ICSR). NOG (NOD/Shi-scid/IL-2Rγnull) mice were injected with 1 million luciferase-expressing NALM-6 leukemia cells. After establishment of leukemia, the mice were imaged and randomized for treatment with the indicated T cell populations at 1 million T cells per mouse; untransduced T cells were used as negative control. Day -1 represents tumor burden before T cell infusion. CAR T cells were able to control leukemia cells two weeks after infusion, while control T cell-treated mice succumbed to leukemia. Notably, ICSR-grown CAR T cells controlled leukemia in 5 out of six mice while serum-grown CAR T cells failed to control leukemia by day 49.
Acknowledgement
We thank James L. Riley and Andrew Medvec from the University of Pennsylvania, Department of Microbiology for their support in generating this data.
